Every Form 4 that MetLife, Inc. (MET) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MET and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MET filings page.
Hay Laura J reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Laura J. Hay received a grant of 721 shares of common stock valued at $71.17 per share as part of non-management director compensation. After this award on April 1, 2026, she directly holds 5,692 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock, and Hay elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This is a routine, compensation-related share award rather than an open-market purchase.
MCKENZIE DIANA reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Diana McKenzie received a grant of 721 shares of common stock, valued at $71.17 per share, as part of non-management director retainer fees. Following this award, she directly holds 24,472 shares. She elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Glaser Daniel S reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Daniel S. Glaser received an equity award of 721 shares of common stock, valued at $71.17 per share. The award represents a portion of his non-management director retainer fees paid in stock. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this grant, Glaser directly holds 2,101 shares of MetLife common stock. In addition, 198 shares are held indirectly in a GRAT, reflecting an estate-planning vehicle associated with his holdings.
GUTIERREZ CARLOS M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carlos M. Gutierrez received a grant of 721 shares of MetLife common stock on April 1, 2026. The shares were awarded at no cash cost as part of non-management director retainer fees paid in stock. Following this award, he directly holds 25,745 common shares and indirectly holds 18,807 additional shares through the Carlos M. Gutierrez Trust.
WEINBERGER MARK A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Mark A. Weinberger received 721 shares of MetLife common stock as a grant tied to his non-management director retainer fees. The shares were awarded at no cash cost per share and increased his direct holdings to 18,801 shares of MetLife common stock.
Johnson Jeh C. reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Jeh C. Johnson received 721 shares of common stock as a compensation award. The grant was valued at $71.17 per share and increased his directly held position to 8,850 shares.
A footnote explains that a portion of non-management director retainer fees is paid in MetLife common stock, and Johnson elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This indicates the transaction is a routine equity-based board compensation event rather than an open-market purchase or sale.
MetLife Inc. director Daniel S. Glaser reported an acquisition of 273 shares of common stock as a grant under non-management director compensation arrangements. The grant was valued at $75.34 per share, and he elected to defer receipt of these shares into the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Glaser directly holds 1,380 common shares. The filing also notes 198 common shares held indirectly in a Grantor Retained Annuity Trust, which were previously reported as directly owned due to an administrative error and are now correctly classified as indirectly held.
MetLife director Diana McKenzie reported a small compensation-related share increase. She acquired 189 shares of MetLife common stock on an imputed basis at $70.60 per share through reinvested dividends in the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, she directly holds 23,751 common shares, reflecting routine deferred compensation rather than an open-market purchase.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 65 shares of MetLife common stock on March 10, 2026 at an imputed price of $70.60 per share. The filing states this resulted from imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
After this award, Johnson directly holds 8,129 MetLife common shares. The footnote explains that the deferred shares represent MetLife common stock that has become payable, but whose receipt Johnson has chosen to defer.
MetLife director Robert Glenn Hubbard received 771 shares of Common Stock at $70.60 per share as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors.
The footnote explains this was an imputed reinvestment of dividends on deferred shares. After this compensation-related acquisition, he directly holds 104,630 MetLife shares.
MetLife Inc director Laura J. Hay acquired 40 shares of common stock on March 10, 2026 at $70.60 per share. The filing describes this as a grant or award, specifically an imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
Following this transaction, Hay directly holds 4,971 shares of MetLife common stock. The deferred shares have become payable, but she has chosen to defer actual receipt of the shares.
MetLife Inc. director William E. Kennard acquired additional common stock through a compensation-related award. On 2026-03-10, he received 365 shares of MetLife common stock at $70.60 per share, reflecting imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this award, Kennard directly holds 45,780 MetLife common shares. He also has an additional 10 shares held indirectly through the MetLife Policyholder Trust, which was established to hold stock allocated to eligible policyholders. These transactions are non-open-market and arise from director compensation and trust holdings rather than discretionary buying or selling.
MetLife director Christian Stephane Mumenthaler acquired 17 shares of common stock as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors. The award, recorded at a reference price of $70.60 per share, brings his directly held MetLife shares to 2,125.
MetLife Inc director Carla A. Harris reported acquiring 43 shares of common stock on March 10, 2026 at $70.60 per share. The filing explains this was an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this award, Harris directly holds 9,764 MetLife common shares. The transaction reflects compensation-related dividend reinvestment rather than an open-market stock purchase.
MetLife Inc. executive John D. McCallion reported a tax-related share disposition. On March 2, 2026, 6,985 shares of MetLife common stock were withheld at $73.24 per share to cover taxes on vested restricted stock units. After this non-market transaction, he directly owned 275,194 shares.
MetLife Inc executive Shurawl Sibblies, EVP & Chief HR Officer, reported a tax-withholding disposition related to restricted stock units. On March 2, 2026, 220 shares of common stock were withheld at $73.24 per share for taxes, leaving her with 28,036 directly owned shares.
MetLife Inc. executive Marlene Debel, EVP & Chief Risk Officer, reported a tax-related share disposition. On the reported date, 4,133 shares of MetLife common stock were withheld to cover taxes on shares issued from restricted stock units. After this withholding, she directly held 154,380 shares.
MetLife Inc. President & CEO Michel Khalaf reported a tax-related share disposition tied to restricted stock units. On this Form 4, 22,420 shares of common stock were withheld at $73.24 per share to cover taxes, a non‑market transaction. After this withholding, he directly holds 697,709 shares of MetLife common stock.
MetLife executive Bill Pappas had 5,989 common shares withheld for taxes at $73.24 per share related to restricted stock units. After this tax-withholding disposition, he directly holds 83,746 common shares. He also reports indirect holdings of 10,220 shares in a 2024 GRAT and 18,750 shares in a 2025 GRAT.
MetLife Inc. executive Ramy Tadros reported a tax-related share disposition. On this Form 4, 5,166 shares of MetLife common stock were withheld on March 2, 2026 at $73.24 per share to cover taxes on shares issued from restricted stock units. After this withholding, Tadros directly holds 216,819 MetLife shares.
MetLife Inc.'s Executive Vice President and Chief Legal Officer, Monica M. Curtis, reported a tax-related share disposition on a Form 4. On March 2, 2026, 953 shares of MetLife common stock were withheld at $73.24 per share to cover taxes on shares issued from restricted stock units. After this tax-withholding disposition, she directly owned 17,646 shares of MetLife common stock.
MetLife Inc. President, U.S. Business, Ramy Tadros reported stock-based compensation activity. He received 19,910 restricted stock units under a 2025 stock and incentive plan and 23,006 common shares from a 2023–2025 performance share award, deferring 80% of that payout. To cover taxes on the performance share payout, 2,299 shares were withheld at a price of $75.34 per share. After these awards and tax withholding, he directly owns 221,985 MetLife common shares.
MetLife, Inc. reported a director stock award. Non-management director Michelle Seitz acquired 273 shares of MetLife common stock on a grant basis, with a reported price of $0.00 per share.
After this award, she directly holds 273 common shares, reflecting compensation paid in stock under MetLife’s non-management director fee arrangements.
MetLife Inc. EVP & Chief Risk Officer Marlene Debel reported equity compensation transactions in company common stock. On February 24, 2026, she acquired 15,132 shares at no cost as a restricted stock unit award under MetLife’s 2025 Stock and Incentive Compensation Plan and 14,870 shares from the performance-based payout of a 2023–2025 performance share award.
On the same date, 5,624 shares at $75.34 per share were withheld to cover her tax obligations related to the performance share payout. After these transactions, she directly owned 158,513 MetLife common shares. These movements reflect stock-based compensation and related tax withholding, not open‑market buying or selling.
MetLife Inc EVP & Chief Legal Officer Monica M. Curtis reported equity awards and related tax withholding transactions in company stock. On February 24, 2026, she received a grant of 7,964 shares of common stock as a restricted stock unit award under MetLife’s 2025 Stock and Incentive Compensation Plan.
She also acquired 420 shares of common stock from the performance-based payout of a 2023–2025 performance share award under MetLife’s 2015 Stock and Incentive Compensation Plan. To cover taxes on this performance share payout, 237 shares were withheld at a price of $75.34 per share. After these transactions, her directly held common stock position was reported at 18,599 shares.
MetLife Inc. executive Bill Pappas reported equity awards and related tax withholding transactions in company stock. On February 24, 2026, he acquired 20,508 and 22,866 shares of MetLife common stock at $0 per share through stock awards, and 11,683 shares were withheld at $75.34 per share to cover tax obligations. After these transactions, he directly owned 89,735 shares. The filing also notes additional indirect holdings of 10,220 and 18,750 shares through 2024 and 2025 Grantor Retained Annuity Trusts.
O'Neill Adrienne Karen reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc executive Adrienne Karen O'Neill, EVP & Chief Accounting Officer, received an equity grant of 2,655 shares of common stock on February 24, 2026. The shares were awarded at $0.00 per share as a restricted stock unit award under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan, increasing her directly owned holdings to 14,557 shares.
Sibblies Shurawl reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc executive Sibblies Shurawl received an equity award of 6,372 shares of common stock on February 24, 2026. The shares were granted at a price of $0.00 per share as a restricted stock unit award under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan, increasing Shurawl’s direct holdings to 28,256 shares.
MetLife Inc President & CEO Michel Khalaf reported stock-based compensation and related tax withholding. He acquired 69,286 shares of common stock through a restricted stock unit award under MetLife’s 2025 Stock and Incentive Compensation Plan and 81,364 shares from the payout of a 2023–2025 performance share award.
To cover tax obligations on the performance share payout, 43,004 shares were withheld at a price of $75.34 per share, treated as a disposition for tax withholding purposes rather than an open-market sale. After these transactions, Khalaf directly owned 720,129 shares of MetLife common stock.
MetLife Inc director Daniel S. Glaser reported an acquisition of 273 shares of MetLife common stock on February 24, 2026 as a grant or award. The shares, valued at $75.34 per share, increased his direct holdings to 1,578 shares and were deferred under MetLife’s non-management director deferred compensation plan.
MetLife EVP & Chief Financial Officer John D. McCallion reported equity awards and related tax withholding in company stock. On February 24, 2026, he acquired 23,892 shares of common stock as a restricted stock unit award under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan.
On the same date, he acquired 26,934 additional common shares from the performance factor determination and payout of a 2023–2025 performance share award under the MetLife, Inc. 2015 Stock and Incentive Compensation Plan. Also on that date, 13,776 shares were disposed of to satisfy his tax withholding obligation on the performance share payout at a price of $75.34 per share.
Following these transactions, McCallion directly owned 282,179 shares of MetLife common stock.
MetLife, Inc. filed a report showing a director acquired additional common stock as part of standard board compensation. On 01/02/2026, the director received 639 shares of MetLife common stock at a price of $80.32 per share, recorded as an acquisition. After this transaction, the director beneficially owned 8,064 shares held directly.
The company explains that non-management directors receive a portion of their retainer fees in MetLife common stock. In this case, the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the award reflects compensation rather than an open-market purchase.
MetLife, Inc. director reported receiving common stock as part of non-management director compensation on 01/02/2026. The filing shows an acquisition of 639 shares of MetLife common stock at $80.32 per share, bringing the director's directly held position to 45,415 shares. An additional 10 shares are reported as indirectly owned through the MetLife Policyholder Trust.
The company’s arrangements pay a portion of non-management director retainer fees in MetLife common stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife, Inc. disclosed that one of its directors received 639 shares of MetLife common stock on 01/02/2026 as part of non‑management director compensation, at a reported price of $0 per share. After this grant, the director beneficially owned 18,080 shares of MetLife common stock in direct ownership. The company notes that its compensation arrangements pay a portion of non‑management director retainer fees in MetLife common stock rather than cash.
MetLife, Inc. reported a routine director equity compensation transaction. A non-management director acquired 639 shares of MetLife common stock on 01/02/2026 at $80.32 per share as part of the standard director retainer paid in stock. Following this transaction, the director beneficially owned 2,108 shares directly.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning the stock represents compensation that is being deferred rather than an open-market purchase.
MetLife, Inc. disclosed that one of its non-management directors received additional common stock as part of regular board compensation. On 01/02/2026, the director acquired 639 shares of MetLife common stock at a stated price of $0 per share, reflecting stock paid in lieu of a portion of cash retainer fees. Following this transaction, the director beneficially owns 33,990 shares of MetLife common stock in direct ownership. The filing notes that MetLife’s non-management director compensation arrangements provide that a portion of director retainer fees is paid in MetLife common stock.
MetLife, Inc. director Carlos M. Gutierrez reported receiving additional common stock as part of non-management director compensation. On 01/02/2026, he acquired 639 shares of MetLife common stock at a price of $0 per share, reflecting payment of a portion of his retainer fees in stock rather than cash. Following this transaction, he beneficially owns 25,024 shares directly and 18,807 shares indirectly through the Carlos M. Gutierrez Trust.
METLIFE, INC. reported that one of its directors acquired common stock as part of standard non-management director compensation. On 01/02/2026, the director received 639 shares of MetLife common stock at a price of $80.32 per share, recorded as an acquisition. After this transaction, the director beneficially owned 9,721 shares of MetLife common stock in direct ownership.
A portion of non-management director retainer fees is paid in MetLife common stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The filing is made by one reporting person in the capacity of a director.
MetLife, Inc. disclosed that one of its non-management directors acquired 639 shares of MetLife common stock on 01/02/2026 at a price of $80.32 per share. This transaction was reported as an acquisition related to the director's compensation.
After this transaction, the director beneficially owns 23,562 shares of MetLife common stock in direct ownership. The filing explains that MetLife's non-management director compensation includes payment of part of retainer fees in MetLife common stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife, Inc. reported that one of its non-management directors acquired 1,105 shares of MetLife common stock on 01/02/2026 at a price of $80.32 per share. This was part of the standard director compensation program, under which portions of board and board chair retainers are paid in MetLife common stock rather than cash.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 103,859 shares of MetLife common stock in direct ownership.
MetLife, Inc. reported a routine insider equity transaction involving one of its non-management directors. On 01/02/2026, the director received 639 shares of MetLife common stock as part of non-management director retainer fees, at a price of $80.32 per share. After this award, the director beneficially owned 4,931 shares of MetLife common stock held directly.
The filing notes that MetLife’s compensation arrangements pay a portion of non-management director fees in company stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This reflects standard equity-based compensation rather than an open-market purchase or sale.
MetLife, Inc. reported that one of its directors acquired additional common stock through a routine plan-related transaction. On 12/09/2025, the director obtained 687 shares of MetLife common stock at $77.82 per share, described as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director beneficially owns 102,754 shares of MetLife common stock in direct form.
A MetLife, Inc. director reported a small increase in holdings through automatic dividend reinvestment under the company’s Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director acquired 11 shares of MetLife common stock at $77.82 per share via an imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owns 1,469 shares of MetLife common stock in direct form. The transaction was reported on a Form 4 as required for company insiders.
MetLife, Inc. director reports additional common stock from dividend reinvestment. On 12/09/2025, the director acquired 324 shares of MetLife common stock at $77.82 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. After this transaction, the director beneficially owned 44,776 shares directly and 10 shares indirectly through the MetLife Policyholder Trust, which holds stock allocated to eligible policyholders of Metropolitan Life Insurance Company.
MetLife, Inc. reported a small insider activity by one of its directors. On 12/09/2025, the director acquired 54 shares of MetLife common stock through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a price of $77.82 per share. Following this automatic dividend reinvestment, the director directly beneficially owns 7,425 shares of MetLife common stock.
MetLife, Inc. director reported a routine change in ownership of common stock linked to a compensation plan. On 12/09/2025, the director acquired 31 shares of MetLife common stock at $77.82 per share through imputed dividend reinvestment on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, the director directly beneficially owned 4,292 MetLife common shares. The filing notes that deferred shares are amounts that have become payable but that the director has chosen to defer receiving.
MetLife, Inc. filed a Form 4 reporting that one of its directors acquired additional common shares through an automatic dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director was credited with 166 shares of MetLife common stock at a price of $77.82 per share, described as imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owned 22,923 MetLife common shares in direct form.
MetLife, Inc. reported a small insider share acquisition by one of its directors. On 12/09/2025, the director acquired 34 shares of MetLife common stock at $77.82 per share, increasing the director’s beneficial ownership to 9,082 shares, held directly.
The transaction reflects imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Under this plan, directors can defer receipt of shares that have become payable, with dividends on those deferred shares reinvested in additional deferred share units.
MetLife (MET) reported an insider administrative transaction by its EVP & Chief Legal Officer. On 10/31/2025, 4,420 shares of common stock were withheld at $79.82 under transaction code F, which indicates shares withheld to cover taxes on restricted stock units.
After this transaction, the reporting person directly owned 10,452 shares.
MetLife, Inc. (MET) disclosed an insider equity transaction by its EVP & Chief Accounting Officer. On 10/31/2025, the officer acquired 11,902 shares of common stock, reported as directly owned after the transaction. A footnote indicates these shares relate to restricted stock units, each representing the right to receive one share of MetLife common stock.
This filing records an equity award event and updates the officer’s reported holdings; it does not reflect an open‑market purchase or sale.